Kornimate/medical-research-clean huggingface dataset:
development and validation of a personalized digital healthcare model for managing side effects in breast cancer survivors

Conditions: Breast Cancer Survivorship; Breast Cancer; Digital Health

Summary: the ultimate goal of this research and development is to develop personalized digital healthcare technologies and self-management strategies based on self-assessment results and evidence, for breast cancer survivors who require management and recovery from acute and chronic side effects related to various treatments (surgery, chemotherapy, radiation, hormone therapy, etc.). additionally, the aim is to verify the clinical applicability and establish a service model to address the diverse unmet healthcare needs of breast cancer survivors.


Eligibility criteria:
inclusion criteria: * individuals who have undergone surgery for stage 1-2 breast cancer * individuals who have had a unilateral mastectomy * aged 18 years or older and under 65 years * possessing a smartphone with either an android or ios operating system * individuals who voluntarily decide to participate after receiving detailed information about the study and provide written consent exclusion criteria: * individuals who have undergone mastectomy only and are not receiving chemotherapy, radiation, or hormone therapy * individuals with severe comorbidities (such as underlying diseases, neuromuscular disorders, cognitive or mental impairments, visual disabilities, etc.) that make it difficult to use the application or participate in the exercise intervention discontinuation criteria * individuals who undergo delayed breast reconstruction surgery during the study period * individuals who develop severe complications or experience cancer metastasis or recurrence in other organs during the study period, leading to a change in treatment * occurrence of a major illness unrelated to study participation * failure to comply with the instructions of the study physician * situations where the participant voluntarily withdraws from the study or becomes unable to continue participating
superior gluteal neuropathy -total hip arthroplasty

Conditions: ElectroPhys: Mononeuropathy

Summary: a prospective study of 50 consecutive patients undergoing total hip arthroplasty, to establish whether there greater incidence of injury to the superior gluteal nerve associated with a particular approach (modified direct lateral approach). the patients will be assessed clinically and electrophysiologically before and after the operation through one year.

neurological complications following total hip arthroplasty are uncommon, and their impact ranges from transient and trivial to permanent and devastating. in general, the prevalence rate of neurologic injury after primary hip arthroplasty is estimated as 0.7-3.5% , whereas it may increase up to 7.6% after revision hip arthroplasty. direct or indirect injuries of nerves may occur during operative exposure and subsequent procedures. injuries to the peripheral nerves can come about in several ways: laceration, ischemia, mechanical deformation from compression or distraction, or a combination of these causes. peripheral nerve injuries can involve either distant sites or nerves in the immediate vicinity of the hip joint. sciatic nerve injury is the most common nerve to be injured following total hip arthroplasty. femoral nerve injury is much less common and is associated with an anterior approach. its diagnosis is often delayed, but the prognosis is generally better than with sciatic nerve injury. the direct lateral approach to the hip was described by hardinge and is based on the observation that the gluteus medius and vastus lateralis are in functional continuity through the thick tendinous periosteum covering the greater trochanter. this approach involves splitting the gluteus medius and retracting a portion of the muscle anteriorly in continuity with part of the vastus lateralis. it avoids trochanteric osteotomy, but the neurovascular supply of gluteus medius and tensor fascia lata is vulnerable. the superior gluteal nerve may be compromised during total hip arthroplasty done through the direct lateral approach of hardinge which puts this nerve at risk when the gluteus medius is split and retracted anteriorly. the function of the abductors may be impaired after operation if there is damage to the superior gluteal nerve or if the muscle flap is reattached inadequately to the trochanter.

Eligibility criteria:
inclusion criteria: * age: adults * sex: both males and female * operation: unilateral primary total hip replacement exclusion criteria: * patient refusal * patients with pre-existing neuromuscular abnormality * preoperative immobility * patient with bilateral total hip arthroplasty or hip pathology * revision hip arthroplasty

Keywords: nerve injury after total hip arthroplasty
adderall xr and processing speed in multiple sclerosis (ms)

Conditions: Impaired Processing Speed; Cognitive Impairment; Multiple Sclerosis

Summary: cognitive impairment, or problems with thinking and memory, is common in multiple sclerosis (ms) and can occur independently of physical disability. it is the most common reason, along with physical fatigue, for ms patients to stop working. the most frequent complaint is problems with multi-tasking or thinking quickly, which corresponds to impairment in the cognitive domain of processing speed. currently there is treatment available to prevent relapses and physical disability but there are no medications that have been shown to treat cognitive impairment. amphetamines have been beneficial for selective attention and processing speed in attention deficit hyperactivity disorder (adhd) and traumatic brain injury. this is study will determine whether adderall xr improves objective measures of processing speed and attention in ms patients impaired in this cognitive domain, by comparing two doses of adderall xr (5 and 10mg) to placebo before and after the medication is administered. the results of this study will help provide data to design a larger study to determine if adderall xr, and potentially other amphetamine drugs, will help treat cognitive impairment in ms patients.


Eligibility criteria:
inclusion criteria: * - males/females who are ≥ 18 years old and ≤ 59 years old * relapsing remitting, secondary progressive or primary progressive ms, as per revised mcdonald's criteria * have not received corticosteroids in last thirty days or a relapse in the last ninety days * an expanded disability status scale (edss) of ≤ 6.5 * if female, must neither be pregnant nor breast-feeding exclusion criteria: * - have evidence of other medical cause(s) of cognitive impairment * have evidence of major depression as determined by a positive beck depression index-fast screen ≥ 13and/or by clinician interview or evidence of severe fatigue with a fatigue severity scale ≥ 5. * have demonstrated a hypersensitivity to amphetamines in the past * have uncontrolled or labile hypertension (\> 135/85 mm hg, treated or untreated) * have a history of structural heart disease, including atherosclerosis or angina * have a diagnosis of bipolar disorder or a history of a psychotic episode * the following medications are not permitted to be used within 14 days the study 1. monoamine oxidase inhibitors 2. sympathomimetics or methadone 3. antipsychotic agents 4. modafinil * the following medications are permitted if the dose has been stable for ≥ 28 days 1. short acting benzodiazepines, qhs administration only 2. anticonvulsants, including gabapentin and pregabalin 3. bupropion 4. tricyclic antidepressants 5. anti-spasmodics such as baclofen or tizanidine 6. anticholinergic medication 7. selective serotonin(-norepinephrine) reuptake inhibitors

Keywords: cognitive impairment multiple sclerosis processing speed treatment
effects of neurocognitive therapy with and without soft robotic hand on hand function

Conditions: Stroke

Summary: to determine the effect of neurocognitive therapy with and without a soft robotic hand on manual ability, dexterity, strength, spasticity and upper limb function in sub-acute stroke.

stroke is a global disease with high death rate and high disability caused by motor cortical damage. according to the calculations, there were approximately 13.68 million new increased stroke patients all over the world a year and about 70% of survivors had diﬀerent degrees of upper limb and hand movement dysfunction .the recovery rate of patients' motor function mainly depends on rehabilitation training. therefore, due to individual diﬀerence of patients. neurocognitive therapy is an effective therapy to improve and increase cognitive, sensory and motor function of upper limb. robotic hand also help the function of weak hand muscle. neurocognitive therapy with a robotic hand will have the potential to offer targeted, precise, and adaptable interventions, possibly increase the rehabilitation process compared to both interventions alone. evaluating their relative efficacy will aid in refining and tailoring rehabilitation strategies for individuals recovering from acute stroke.

Eligibility criteria:
inclusion criteria: * participants of post stroke patients (6-12 weeks ) * participants with spasticity \< 2 on modified ashworth scale. * participants with first ever stroke. * participants with normal cognition \> 24 on moca * participants must be able to provide informed consent * hemiparesis with arm motor deficit as assessed by with nihss \>1(14) exclusion criteria: * participants who have a history of significant neurological or orthopedic disorders, other than stroke, that could interfere with upper limb motor or sensory recovery. * participants who have altered state of consciousness, severe aphasia, severe cognitive deficit. * participants who have severe pathologies of traumatic and or rheumatic nature, severe pain in effected arm (\>5 on visual analog scale for pain) . * participants who have active pacemakers and other active implants.

Keywords: hand function,cognitive, stroke rehabilitation
effects of exercises on functional capacity

Conditions: Nicotine Addiction; Respiratory Disease; Sedentary Behavior

Summary: in this study, the researchers aim to investigate the effects of strengthening and respiratory exercises on the face and online on functional capacity.

the american sports medical association has reported that a regular exercise program containing endurarans, strength, flexibility, and neuromotor exercise training is required in addition to daily life activities in order to maintain and develop general health. in addition to the increase in muscle strength with resistant exercises, durability and strength are also targeted. when performing resistant exercise, it is important to breathe correctly. the speed of the exercise and the movements are performed throughout the furnishing openness of the joint movement. the effects of exercise on being healthy and good are mentioned in the literature in detail. however, the effects of exercise on the respiratory functions and functional capacity of young people who smoke are not adequately defined. for this reason, the researchers plan to research the effects of strengthening and respiratory exercises on the face and online on functional capacity.

Eligibility criteria:
inclusion criteria: signing the illuminated consent form, being smoking at least 1 cigarette for the last 6 months, not having orthopedic or neurological findings that can prevent the exercises included in the study, to have a low- to medium-level physical activity level, not to have any lower respiratory infection in the last 3 months. exclusion criteria: the exercise sessions to be held on time and regularly.

Keywords: nicotine addiction respiratory exercise telehealth resistance exercise
timing of specific exercise therapy after breast cancer surgery: early versus delayed initiation

Conditions: Breast Cancer

Summary: this single-center, parallel-group randomized controlled trial (rct) will compare two timings for initiating specific exercise therapy after breast cancer surgery. the study tests whether early initiation (within the first postoperative week) versus delayed initiation (at 3 weeks postoperative) results in superior upper limb function at 6 months as measured by the disabilities of the arm, shoulder, and hand (dash) questionnaire. secondary outcomes include pain intensity (visual analog scale, vas) and wound-related complications such as drainage time and hematoma incidence.


Eligibility criteria:
inclusion criteria: * women aged 18-65 years. * scheduled to undergo breast cancer surgery with axillary node dissection. * at risk for upper limb morbidity based on preoperative assessment. * able to provide informed consent and complete study questionnaires. * willing and able to attend scheduled physiotherapy sessions and follow-up evaluations. exclusion criteria: * diagnosis of recurrent or metastatic breast cancer. * concurrent participation in another rehabilitation intervention or clinical trial. * severe comorbidities (e.g., uncontrolled cardiovascular disease, severe orthopedic conditions) that preclude safe participation. * history of previous shoulder surgery or chronic upper extremity musculoskeletal disorders unrelated to breast cancer treatment. * inability to understand or complete study materials in english. * pregnancy or lactation.
minimization of surgical site infections for pts undergoing colorectal surgery

Conditions: Surgical Wound Infections; Colorectal Surgery

Summary: this is a comparison, at this va hospital, of standard operating room management in colorectal surgery to a more rigid management using an additional five previously tested treatments to determine if this changes the rate of post operative wound infections.

a comparison between standard operating room: 1. use of pre-op bowel prep (golytely or phosphosoda,plus 3 doses of oral antibiotics(erythromycin and neomycin), and fleets enema the day before surgery 2. standard anesthesia fio2 (approx. 30-50%)during surgery 3. standard iv fluids during surgery(greater than 200cc per hour) 4. standard post-op o2 by mask for 2 hours to extended operating room procedures of: 1. no po antibiotics or pre-op bowel prep other than enema prior to surgery 2. skin warming at least 15 minutes prior to and during surgery(core temp 36c+) 3. ioban drapes and plastic wound protectors used during surgery 4. restricted iv fluids less than 200cc per hour during surgery 5. increased fio2 to 80% during surgery and 2 hours after by mask monitoring for post-op wound infections at discharge and up to 30days post-op

Eligibility criteria:
inclusion criteria: * scheduled va adult elective colorectal surgery patient exclusion criteria: * non va adults, emergent colorectal surgery, scheduled multiple surgery procedures,pts with other infections being treated

Keywords: surgery wound infections colorectal
hr20013 for nausea and vomiting associated with moderate emetic risk anticancer agents

Conditions: Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Summary: this study is aimed to evaluate the efficacy and safety of hr20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older, of either gender 2. has a histologically or cytologically confirmed malignant disease 3. naïve to cytotoxic chemotherapy 4. scheduled to receive first course of moderate emetic risk anticancer agents 5. predicted life expectancy of ≥ 3 months 6. has a performance status (ecog scale) of 0 to 1 7. adequate organ function 8. female subjects of childbearing potential must have a negative blood pregnancy test within 72 hours before randomization; and must be non-lactating; 9. able and willing to provide a written informed consent exclusion criteria: 1. received or planned to receive total body irradiation, or radiation therapy to the abdomen, pelvis, whole brain and spinal cord, head and neck , or chest within 7 days before randomization or within days 1 to 8 of treatment 2. scheduled to receive any moderate emetic risk anticancer agents from day 1 to 6 3. planned to receive treatment with a chemotherapy regimen including ordinary paclitaxel (with castor oil as solvent); 4. medications with potential antiemetic efficacy within 2 days before randomization; 5. began using opioids within 7 days prior to randomization or had a dose adjustment within the last 7 days. 6. systemic corticosteroid therapy or sedative antihistamines within 7 days before randomization; 7. use of palonosetron within 14 days before randomization; 8. use of nk-1 receptor antagonists within 28 days before randomization; 9. use of moderate to strong cyp3a4 inhibitors within 7 days before randomization; use of moderate to strong cyp3a4 inducers or specific cyp2d6 substrates within 28 days before randomization; 10. vomiting and/or retching and nausea within 24 hours before randomization; 11. subjects with symptomatic brain metastases, or with any symptoms suggestive of brain metastases or intracranial hypertension; 12. with uncontrolled serosal effusion; 13. patients with serious cardiovascular diseases; 14. concurrent uncontrolled hypertension before randomization; 15. patients with active hepatitis b, active hepatitis c, acquired immunodeficiency syndrome (aids) or hiv test positive, and active syphilis test positive; 16. concomitant diseases where dexamethasone is contraindicated; 17. the presence of severe or inadequately controlled diseases; 18. known contraindications to nk-1 receptor antagonists, 5-ht3 receptor antagonists, or dexamethasone; 19. participation in another clinical trial within 30 days prior to randomization (based on the use of study medication); 20. the presence of severe emotional or psychiatric disorders, as assessed by the investigator as unsuitable for participation in this study; 21. subjects who, in the opinion of the investigator, have other conditions that make them inappropriate for participation in this study.
the role of diet and lifestyle in breast cancer survival

Conditions: Breast Cancer

Summary: diet has been found to influence hormone production and metabolism which in turn could affect the incidence of hormone related cancers. consumption of soy-containing foods, known to be rich in phytoestrogens, is thought to be one of the chemoprotective factors against breast cancer in asian populations. phytoestrogens have a wide range of metabolic effects and may have a role in effecting breast cancer risk. although there is mounting evidence of the positive influence of phytoestrogens on breast cancer risk, very little research has been carried out in humans as to the effects of phytoestrogens on breast cancer recurrence and survival. the dietcomplyf study aims to explore this effect by carrying out an observational study in 3,000 breast cancer women in the uk. the effects of diet, lifestyle practices and use of complementary treatments will also be investigated. participants are recruited 9-15 months post-diagnosis and followed up for 5 years. questionnaires as well as blood and urine samples are collected annually.

women matching the eligibility criteria are consented at breast cancer follow-up hospital visits. blood and urine samples are then collected and questionnaires are provided for the participants to take away and return within 4 weeks. the process of sample collection and questionnaire provision is repeated for visit at years 3 and 5. year 2 and 4 study visit vary in that questionnaires including a 7 day food diary are sent to participants at home to be filled in 7 days before their scheduled follow-up appointment. at hospital, blood and urine samples are collected as usual.

Eligibility criteria:
inclusion criteria: * women with histologically confirmed invasive primary breast cancer grades i to iii. * age up to and including 75 years old exclusion criteria: * previous cancer with the exception of basal cell carcinoma * concomitant primary cancer * bilateral cancer of the breast * psychological problems * cognitive impairment * poor understanding of english

Keywords: phytoestrogens isoflavones lignans breast cancer survival breast cancer recurrence
bfrt for severe lower extremity muscle atrophy

Conditions: Severe Muscle Atrophy; Muscle Weakness

Summary: muscle weakness or atrophy is a common condition following acute and chronic musculoskeletal injuries. strength training is an imperative component in clinical rehabilitation of musculoskeletal injuries. heavy exercise loads (approximately 70% of one repetition maximum) is necessary to elicit muscle hypertrophy and strength gains. however, patients with severe muscle atrophy are frequently unable to tolerate these loads due to pain. blood flow resistance training with low resistance loads may be used to safely develop muscle strength.

blood flow restriction training (bfrt) is a safe type of low intensity resistance exercise that has demonstrated enhanced muscle growth, muscle strength, oxygen delivery and utilization (vo2max). with bfrt, lighter loads can be used to build muscle while sparing the joints from heavy loading and without overly fatiguing the central nervous system. the objectives of bfrt are 1) to increase the effectiveness of physical therapy, 2) safely increase muscle mass, reduce arterial stiffness, increase bone density, increase vo2max, improve carotid arterial compliance and enhance response of the autonomic nervous system, 3) improve muscle endurance in 1/3 the time, improve strength and hypertrophy after surgery, improve muscle recruitment and increase anabolic growth signaling.

Eligibility criteria:
inclusion criteria: * patients with \> 20% deficit in isometric quadriceps and/or hamstrings strength * patients willing to complete at least 9 bfrt training sessions * patients willing to provide informed consent (or parental consent) exclusion criteria: * pregnancy * history of varicose veins * history of blood clots or active blood clot * taking oral contraceptives * history of heart attack * unstable cardiac disease * taking heart failure medication * uncontrolled hypertension (\> 140/90) * uncontrolled tachycardia (\> 100 bpm)
a research study looking at new protein-based tablets in healthy men - oral formulation iv

Conditions: Healthy Volunteers Type 2 Diabetes

Summary: this study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. it is done to test how semaglutide in each of the tablet versions is taken up in the body. which treatments participants will receive is decided by chance. the study will last for about 28 weeks. the study will enroll healthy male participants.


Eligibility criteria:
inclusion criteria: 1. male. 2. age 18-64 years (both inclusive) at the time of signing the informed consent. 3. body mass index (bmi) between 22.0 and 31.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. 4. considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ecg) and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: 1. known or suspected hypersensitivity to study interventions or related products. 2. any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. 3. use of prescription medicinal products or non-prescription drugs, except routine vitamins, topical medication not reaching the systemic circulation and occasional use of paracetamol (acetaminophen) and ibuprofen, within 14 days prior to first dosing.